TVTX
Travere Therapeutics Inc
52.10$
+0.2%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -5.3% | -15.9% | -16.9% | -8.5% | +17.8% | -7.6% | +1.2% | -3.0% | +12.4% | -8.3% | +44.0% | |
| – | -10.1% | -22.0% | -23.3% | -12.0% | +28.3% | -10.2% | +1.4% | -2.2% | +17.9% | -10.3% | +56.7% | |
| – | -59.7% | -25.7% | -25.3% | +12.8% | +60.8% | +5.7% | +21.4% | +47.6% | -16.1% | -15.8% | +50.2% | |
| – | -10.7% | -22.2% | -26.2% | -14.7% | +33.6% | -13.1% | -0.8% | -20.3% | +26.8% | -18.0% | +84.8% | |
| – | +45.4% | +7.3% | +7.6% | +2.9% | +7.7% | +26.8% | +12.6% | +114.3% | -1.9% | +7.2% | -7.6% | |
| – | -54.7% | -51.8% | +31.9% | +6.4% | -2.5% | -36.6% | +4.0% | +35.6% | +5.9% | +8.2% | +23.3% | |
| – | -5.9% | +6.2% | +0.0% | -6.6% | +7.1% | -5.9% | +0.0% | +6.2% | -5.9% | +6.2% | – | |
| – | -2.3% | -3.1% | +4.0% | -0.9% | -0.2% | -0.2% | +1.7% | +3.7% | +4.1% | -3.4% | +20.3% | |
| – | +6.3% | +0.2% | -9.1% | -0.2% | +0.0% | -3.6% | +1.3% | -11.0% | +5.5% | -6.9% | +69.7% | |
| – | +27.6% | -2.6% | -30.0% | +56.7% | +5.6% | -9.1% | +3.9% | -28.7% | +18.4% | -21.6% | +21.2% | |
| – | +2.7% | +2.6% | +2.5% | +1,331.3% | +0.3% | +0.2% | +0.3% | -92.3% | +2.5% | +2.4% | +2.4% | |
| – | +68.5% | -59.9% | +54.5% | -10.2% | +1.5% | -34.7% | +24.5% | -4.8% | +36.1% | -47.9% | -42.0% | |
| – | +0.1% | +0.1% | +0.1% | -18.0% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +93.2% | |
| – | -28.2% | -63.1% | -79.6% | -301.1% | – | -44.4% | -0.2% | +124.6% | +56.1% | -14.0% | -75.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.2% | +0.9% | +0.5% | +0.4% | +6.8% | +6.3% | +0.7% | +15.4% | -12.0% | +1.7% | +1.8% |
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.